Brain volume loss helps in judging DMT efficacy in RRMS: Review
The rate of brain atrophy, or volume loss, may help in determining whether disease-modifying therapies (DMTs) are slowing disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a review of data from 12 published studies found. The analysis, āBrain Atrophy as an Outcome of Disease-Modifying Therapy for…